Published in PLoS Pathog on August 13, 2015
ART influences HIV persistence in the female reproductive tract and cervicovaginal secretions. J Clin Invest (2016) 0.80
In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection. Retrovirology (2016) 0.80
In vivo platforms for analysis of HIV persistence and eradication. J Clin Invest (2016) 0.80
Advancements in nano-enabled therapeutics for neuroHIV management. Int J Nanomedicine (2016) 0.78
Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse Model. Antimicrob Agents Chemother (2016) 0.78
A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges. J Antimicrob Chemother (2016) 0.78
Humanized mice for HIV and AIDS research. Curr Opin Virol (2016) 0.78
HIV pre-exposure prophylaxis for women and infants prevents vaginal and oral HIV transmission in a preclinical model of HIV infection. J Antimicrob Chemother (2016) 0.77
Efficient Inhibition of HIV Replication in the Gastrointestinal and Female Reproductive Tracts of Humanized BLT Mice by EFdA. PLoS One (2016) 0.77
Cellular Responses and Tissue Depots for Nanoformulated Antiretroviral Therapy. PLoS One (2015) 0.76
The potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trials. Nanomedicine (Lond) (2015) 0.76
A Shot in the Arm for HIV Prevention? Recent Successes and Critical Thresholds. AIDS Res Hum Retroviruses (2015) 0.75
Correction: Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission. PLoS Pathog (2015) 0.75
Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission. AIDS (2017) 0.75
Predicting HIV Pre-exposure Prophylaxis Efficacy for Women using a Preclinical Pharmacokinetic-Pharmacodynamic In Vivo Model. Sci Rep (2017) 0.75
In Vivo Models of Human Immunodeficiency Virus Persistence and Cure Strategies. J Infect Dis (2017) 0.75
Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice. PLoS One (2017) 0.75
Long-acting slow effective release antiretroviral therapy. Expert Opin Drug Deliv (2017) 0.75
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (2010) 35.19
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med (2012) 20.03
Preexposure prophylaxis for HIV infection among African women. N Engl J Med (2012) 15.28
Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet (2002) 11.02
Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med (2015) 9.20
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med (2009) 7.01
Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med (2008) 5.81
Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat Med (2006) 5.36
Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1. J Exp Med (2007) 3.75
Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol (2012) 3.41
Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater (2009) 2.87
Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J Virol (2011) 2.55
TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother (2009) 2.44
Generation of HIV latency in humanized BLT mice. J Virol (2011) 2.20
Preexposure prophylaxis for HIV prevention: where have we been and where are we going? J Acquir Immune Defic Syndr (2013) 2.13
Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science (2014) 2.11
In situ-forming hydrogels--review of temperature-sensitive systems. Eur J Pharm Biopharm (2004) 2.08
Inhibition of lysosome and proteasome function enhances human immunodeficiency virus type 1 infection. J Virol (2005) 2.05
Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice. PLoS One (2010) 1.88
The uptake and intracellular fate of PLGA nanoparticles in epithelial cells. Biomaterials (2009) 1.82
Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr Opin HIV AIDS (2013) 1.73
Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur J Pharm Biopharm (2009) 1.70
Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci Transl Med (2012) 1.68
Functional and phenotypic characterization of the humanized BLT mouse model. Curr Top Microbiol Immunol (2008) 1.50
Humanized mouse models of HIV infection. AIDS Rev (2011) 1.49
Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob Agents Chemother (2010) 1.35
Human breast milk and antiretrovirals dramatically reduce oral HIV-1 transmission in BLT humanized mice. PLoS Pathog (2012) 1.30
Immune reconstitution of the female reproductive tract of humanized BLT mice and their susceptibility to human immunodeficiency virus infection. J Reprod Immunol (2011) 1.22
A compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV-negative volunteers for pre-exposure prophylaxis. Clin Pharmacol Ther (2014) 1.20
In vivo distribution of surface-modified PLGA nanoparticles following intravaginal delivery. J Control Release (2011) 1.20
Mucosal HIV-1 transmission and prevention strategies in BLT humanized mice. Trends Microbiol (2012) 1.15
Combination antiretroviral drugs in PLGA nanoparticle for HIV-1. BMC Infect Dis (2009) 1.13
Antiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in mice. J Antimicrob Chemother (2010) 1.07
HIV prevention in women: next steps. Science (2011) 1.04
Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles. Pharm Res (2008) 1.04
Formulation, pharmacokinetics and pharmacodynamics of topical microbicides. Best Pract Res Clin Obstet Gynaecol (2012) 1.01
The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge. Sci Transl Med (2015) 1.01
HIV restriction by APOBEC3 in humanized mice. PLoS Pathog (2013) 1.00
A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge. Sci Transl Med (2015) 0.99
Polymer nanoparticles encapsulating siRNA for treatment of HSV-2 genital infection. J Control Release (2012) 0.95
Thermoreversible gel formulations containing sodium lauryl sulfate or n-Lauroylsarcosine as potential topical microbicides against sexually transmitted diseases. Antimicrob Agents Chemother (2001) 0.91
Formulation of mucoadhesive vaginal hydrogels insensitive to dilution with vaginal fluids. Eur J Pharm Biopharm (2010) 0.89
Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis. Antiviral Res (2012) 0.87
BLT humanized mice as model to study HIV vaginal transmission. J Infect Dis (2013) 0.84
Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings. HIV AIDS (Auckl) (2011) 0.84
Vaginal microbicides and their delivery platforms. Expert Opin Drug Deliv (2014) 0.81
Uptake through glycoprotein 2 of FimH(+) bacteria by M cells initiates mucosal immune response. Nature (2009) 3.18
Intestinal villous M cells: an antigen entry site in the mucosal epithelium. Proc Natl Acad Sci U S A (2004) 2.75
Role of Peyer's patches in the induction of Helicobacter pylori-induced gastritis. Proc Natl Acad Sci U S A (2007) 2.44
Generation of HIV latency in humanized BLT mice. J Virol (2011) 2.20
Rice-based oral antibody fragment prophylaxis and therapy against rotavirus infection. J Clin Invest (2013) 2.15
RANKL is necessary and sufficient to initiate development of antigen-sampling M cells in the intestinal epithelium. J Immunol (2009) 1.73
Indigenous opportunistic bacteria inhabit mammalian gut-associated lymphoid tissues and share a mucosal antibody-mediated symbiosis. Proc Natl Acad Sci U S A (2010) 1.67
Intracellularly expressed TLR2s and TLR4s contribution to an immunosilent environment at the ocular mucosal epithelium. J Immunol (2004) 1.60
Comprehensive gene expression profiling of Peyer's patch M cells, villous M-like cells, and intestinal epithelial cells. J Immunol (2008) 1.58
Establishment of a poliovirus oral infection system in human poliovirus receptor-expressing transgenic mice that are deficient in alpha/beta interferon receptor. J Virol (2007) 1.40
Specific expression of apolipoprotein A-IV in the follicle-associated epithelium of the small intestine. Dig Dis Sci (2014) 1.38
Human breast milk and antiretrovirals dramatically reduce oral HIV-1 transmission in BLT humanized mice. PLoS Pathog (2012) 1.30
Extracellular ATP mediates mast cell-dependent intestinal inflammation through P2X7 purinoceptors. Nat Commun (2012) 1.18
Nef functions in BLT mice to enhance HIV-1 replication and deplete CD4+CD8+ thymocytes. Retrovirology (2012) 1.14
Secretory IgA-mediated protection against V. cholerae and heat-labile enterotoxin-producing enterotoxigenic Escherichia coli by rice-based vaccine. Proc Natl Acad Sci U S A (2010) 1.11
Id2-, RORgammat-, and LTbetaR-independent initiation of lymphoid organogenesis in ocular immunity. J Exp Med (2009) 1.04
Immunological commonalities and distinctions between airway and digestive immunity. Trends Immunol (2008) 1.01
Peyer's patches are required for intestinal immunoglobulin A responses to Salmonella spp. Infect Immun (2007) 1.01
Distinct fucosylation of M cells and epithelial cells by Fut1 and Fut2, respectively, in response to intestinal environmental stress. Biochem Biophys Res Commun (2010) 0.97
M cells expressing the complement C5a receptor are efficient targets for mucosal vaccine delivery. Eur J Immunol (2011) 0.97
Antigen-sampling cells in the salmonid intestinal epithelium. Dev Comp Immunol (2010) 0.94
New horizon of mucosal immunity and vaccines. Curr Opin Immunol (2009) 0.93
NFIL3-deficient mice develop microbiota-dependent, IL-12/23-driven spontaneous colitis. J Immunol (2014) 0.92
Induction of toxin-specific neutralizing immunity by molecularly uniform rice-based oral cholera toxin B subunit vaccine without plant-associated sugar modification. Plant Biotechnol J (2013) 0.91
The airway antigen sampling system: respiratory M cells as an alternative gateway for inhaled antigens. J Immunol (2011) 0.90
Nanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by Streptococcus pneumoniae. Infect Immun (2013) 0.87
Oral MucoRice expressing double-mutant cholera toxin A and B subunits induces toxin-specific neutralising immunity. Vaccine (2009) 0.84
RNAi suppression of rice endogenous storage proteins enhances the production of rice-based Botulinum neutrotoxin type A vaccine. Vaccine (2012) 0.82
ART influences HIV persistence in the female reproductive tract and cervicovaginal secretions. J Clin Invest (2016) 0.80
Expression of newly identified secretory CEACAM1(a) isoforms in the intestinal epithelium. Biochem Biophys Res Commun (2009) 0.80
Progress towards an AIDS mucosal vaccine: an overview. Tuberculosis (Edinb) (2007) 0.80
In vivo molecular imaging analysis of a nasal vaccine that induces protective immunity against botulism in nonhuman primates. J Immunol (2010) 0.79
A soluble nonglycosylated recombinant infectious hematopoietic necrosis virus (IHNV) G-protein induces IFNs in rainbow trout (Oncorhynchus mykiss). Fish Shellfish Immunol (2008) 0.78
Efficient Inhibition of HIV Replication in the Gastrointestinal and Female Reproductive Tracts of Humanized BLT Mice by EFdA. PLoS One (2016) 0.77
Localization of fatty acid binding protein of epidermal type common to dendritic cells and presumptive macrophages in Peyer's patches and epithelial M cells of mouse intestine. Histochem Cell Biol (2009) 0.77
Biological characterisation of a recombinant Atlantic salmon type I interferon synthesized in Escherichia coli. Fish Shellfish Immunol (2007) 0.77
Nanogel-based antigen-delivery system for nasal vaccines. Biotechnol Genet Eng Rev (2013) 0.76
Correction: Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission. PLoS Pathog (2015) 0.75
Localization of interleukin-18 and its receptor in somatotrophs of the bovine anterior pituitary gland. Cell Tissue Res (2005) 0.75